TG Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 940.6, 1242.11, 1572.66, 1956.58, 2244.43 ], "ebit_estimate": [ 266.54, 494.68, 663.7, 844.33, 1012.65 ], "ebitda_estimate": [ 276.55, 492.9, 417.28, null, null ], "net_income_estimate": [ 218.48, 419.9, 508.75, 643.43, 827.28 ], "per_share_eps_estimate": [ 1.37, 2.74, 3.21, 3.86, 4.75 ], "eps_nri_estimate": [ 1.36, 2.75, 3.38, 3.86, 4.75 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 2.33, 4.11, null, null, null ], "pretax_income_estimate": [ 233.7, 465.06, 610.93, 820.47, 1009.6 ], "operating_cash_flow_per_share_estimate": [ 1.25, 3.63, null, null, null ], "roa_estimate": [ 25, 38.6, null, null, null ], "roe_estimate": [ 37.28, 57.5, null, null, null ], "gross_margin_estimate": [ 85, 87, 87, 87, 87 ], "operating_cash_flow_estimate": [ 200.08, 580.23, null, null, null ], "pettm_estimate": [ 41.82, 20.82, 17.79, 14.8, 12.03 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "36.19", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 36.19, "future_ebit_estimate_growth": 76.25, "future_ebitda_estimate_growth": 52.7, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": 80.47, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 1.42, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 228.85, 244.25, 262.58, 278.83, 303.08, 325.41, 355.97 ], "ebit_estimate": [ 69.4, 72.93, 89.68, 100.55, 124, 139.15, 169.8 ], "ebitda_estimate": [ 78.31, 72.2, 93.29, null, null, null, null ], "net_income_estimate": [ 58.55, 59.72, 76.1, 83.55, 106.05, 120.7, 109.5 ], "per_share_eps_estimate": [ 0.37, 0.37, 0.47, 0.53, 0.67, 0.76, 0.69 ], "eps_nri_estimate": [ 0.33, 0.4, 0.5, 0.53, 0.67, 0.76, 0.69 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ 57.08, 65.1, 82.37, 91.05, 114, 129.2, 160.3 ], "operating_cash_flow_per_share_estimate": [ 3.49, 3.99, 5.19, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ 85, 85, 85, 85, 85, 85, 89 ], "operating_cash_flow_estimate": [ 558.62, 638.65, 830.72, null, null, null, null ], "pettm_estimate": [ 32.9, 28.04, 23.54, 21.6, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "36.19", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 36.19, "future_ebit_estimate_growth": 76.25, "future_ebitda_estimate_growth": 52.7, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": 80.47, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 1.42, "future_operating_cash_flow_per_share_estimate_growth": null }